Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Karyopharm Therapeut

(NASDAQ: KPTI)
Add to Portfolio
-0.25 (-1.47%)
as of Dec 13, 2019

Last 16.75
Change -0.25 (-1.47%)
Open 16.88
Prev. Close 17.00
Today's Range
16.60
17.12
52wk Range
3.92
18.70
Volume 585,300
Avg Volume 1,176,500
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
KPTI -1.47% +62.31% +70.74%
DJIA +0.01% +7.38% +14.38%
S&P 500 +0.01% +8.87% +19.55%

Key Statistics

Annual EPS -3.43
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 1,067,740
Weighted Alpha +135.40
Standard Deviation -0.46
Profit Margin N/A
Beta 2.60

Growth Rates

YTD +78.76%
1-Year +74.12%
3-Year +71.79%
5-Year -56.55%

Opinion

Sell Hold Buy

Recent Headlines

Karyopharm Presents XPOVIO(R) (Selinexor) and

GlobeNewswire via COMTEX - Sun Dec 08, 09:00AM EST
-- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis(R) and Low Dose Dexamethasone Demonstrates 71% Overall Response Rate, Including a Complete Response Rate of 21%, in Patients with Heavily Pretreated, Kyprolis-Naive(full story)
KPTI: 16.75 (-0.25)

Karyopharm Reports New and Updated XPOVIO(R)

GlobeNewswire via COMTEX - Sat Dec 07, 09:00AM EST
-- All Oral Regimen of Once Weekly Selinexor in Combination with Daily Pomalyst and Low Dose Dexamethasone Demonstrates 56% Overall Response Rate in Pomalyst-Naive and Revlimid-Relapsed or -Refractory Myeloma with Progression-Free(full story)
KPTI: 16.75 (-0.25)

Shares of Karyopharm Thera Rank the Highest in Terms

Comtex SmarTrend(R) via COMTEX - Thu Dec 05, 03:27AM EST
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.(full story)
CLVS: 12.86 (-0.57), EXEL: 17.82 (+0.17), KPTI: 16.75 (-0.25)

Karyopharm Therapeutics Reports Inducement Grants

GlobeNewswire via COMTEX - Mon Dec 02, 04:05PM EST
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase an aggregate of 84,000 s(full story)
KPTI: 16.75 (-0.25)

Best Relative Performance in the Biotechnology

Comtex SmarTrend(R) via COMTEX - Thu Nov 21, 03:27AM EST
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.(full story)
CTMX: 7.16 (+0.04), KPTI: 16.75 (-0.25), SPPI: 8.36 (-0.34)